Information on the financial toxicity experienced by Japanese patients with metastatic renal cell carcinoma (mRCC) is lacking, even though Japan has its own unique public health insurance system. Thus, a web-based survey was conducted to evaluate the financial toxicity experienced by Japanese mRCC patients using the COmprehensive Score for financial Toxicity (COST) tool. This study enrolled Japanese patients who underwent, or were undergoing, systemic therapy for mRCC. The outcomes evaluated were the distribution of COST scores, the correlation between COST and quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale, and demographic factors associated with financial toxicity. The median (range) COST score was 19.0 (3.0–36.0). The Pearson correlation coefficient for COST and FACT-G total scores was 0.40. Univariate analysis revealed that not having private health insurance and lower household income per year were significantly associated with lower COST scores. Multivariate analyses showed that age < 65 years and not having private health insurance were significantly associated with lower COST scores. This study revealed that Japanese mRCC patients experience adverse financial impacts even under the universal health insurance coverage system available in Japan, and financial toxicity negatively affects their QOL.
尽管日本拥有独特的公共医疗保险体系，但关于日本转移性肾细胞癌患者所经历的经济毒性的信息仍较为缺乏。为此，本研究开展了一项基于网络的调查，采用经济毒性综合评分工具，评估日本转移性肾细胞癌患者的经济毒性状况。研究纳入了正在接受或曾接受转移性肾细胞癌全身治疗的日本患者。评估指标包括经济毒性综合评分的分布情况、经济毒性综合评分与癌症治疗功能评估量表总评分所评估的生活质量之间的相关性，以及与人口统计学因素相关的经济毒性。经济毒性综合评分的中位数（范围）为19.0（3.0–36.0）。经济毒性综合评分与癌症治疗功能评估量表总评分之间的皮尔逊相关系数为0.40。单变量分析显示，未购买私人医疗保险和较低的家庭年收入与经济毒性综合评分较低显著相关。多变量分析表明，年龄小于65岁和未购买私人医疗保险与经济毒性综合评分较低显著相关。本研究揭示，即使在日本的全民医疗保险体系下，转移性肾细胞癌患者仍面临不良的经济影响，且经济毒性对其生活质量产生了负面影响。
肿瘤(癌症)患者之家